Progestin and antiprogestin responsiveness in breast cancer is driven by the <scp>PRA</scp>/<scp>PRB</scp> ratio via<scp>AIB</scp>1 or <scp>SMRT</scp> recruitment to the <scp>CCND</scp>1 and <scp>MYC</scp> promoters

Victoria Wargon; Claudia Lanari

doi:10.1002/ijc.29304

Progestin and antiprogestin responsiveness in breast cancer is driven by the <scp>PRA</scp>/<scp>PRB</scp> ratio via<scp>AIB</scp>1 or <scp>SMRT</scp> recruitment to the <scp>CCND</scp>1 and <scp>MYC</scp> promoters

Victoria Wargon(Consejo Nacional de Investigaciones Científicas y Técnicas), Claudia Lanari(Consejo Nacional de Investigaciones Científicas y Técnicas)

International Journal of Cancer

November 1, 2014

10.1002/ijc.29304

Cited by 39

|Cancer Research|2011|87

Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer

|Endocrine Related Cancer|2018|31

Referee report. For: Impact of estrogen and progesterone hormone receptors on the progression of interferon-γ sensitized breast cancer cells [version 1; peer review: 1 approved, 1 approved with reservations, 1 not approved]

|Faculty of 1000 Research Ltd|2024|0

Progestin and antiprogestin responsiveness in breast cancer is driven by the <scp>PRA</scp>/<scp>PRB</scp> ratio <i>via</i><scp>AIB</scp>1 or <scp>SMRT</scp> recruitment to the <scp><i>CCND</i></scp><i>1</i> and <scp><i>MYC</i></scp> promoters

Related Papers